Kornimate/medical-research-clean huggingface dataset:
ctbs targeting cerebellum for drug-refractory epilepsy

Conditions: Drug Refractory Epilepsy

Summary: this study aims to observe the effect and safety of cerebellar continuous θ burst stimulation (ctbs) for drug-refractory epilepsy(dre), in order to provide a new treatment for dre and improve the quality of life of those patients. a total of 44 patients with dre will have ctbs via accurate navigation to bilateral cerebellar dentate nuclei. patients will be randomised into 2 groups in a crossover trial design to have 2 week periods of ctbs separated by 8 week washout periods, following which the patient will cross over to have the opposite condition for a further 2 week. frequency and symptoms of seizures, scalp eeg, clinical scores, and qolie-31 were assessed at baseline and after 1 and 2 month of treatment.


Eligibility criteria:
inclusion criteria: * a) participants who are in line with the diagnostic criteria for epilepsy, * b) participants who are diagnosed as drug-refractory epilepsy, * c) participants who has duration of epilepsy ≥2 years and seizure frequency ≥2 times per month, * d) the type and dosage of anti-epileptic drugs do not change during the experiment, * e) participants or their families reject invasive therapy, such as operation, * f) participants and their families are aware of this study and sign informed consent. exclusion criteria: * a) participants who are in status epilepticus, * b) participants who are complicated with serious infection, cerebrovascular disease, malignant tumor and other nervous system diseases, with serious dysfunction of heart, liver, kidney and other organs, and with psychiatric disorders, * c) participants who are diagnosed as syncope, hysteria or other non-epileptic attacks, * d) participants who are in pregnancy or lactating, * e) participants who have incomplete clinical data, * f) patients have contraindications of repeated transcranial magnetic stimulation.

Keywords: drug refractory epilepsy continuous θ burst stimulation cerebellar dentate nucleus
symptomatic and incidental rcc detection

Conditions: Renal Cell Carcinoma (Kidney Cancer); Benign Renal Neoplasm; Renal Carcinoma

Summary: evaluation of the frequency of symptomatic and incidental detection of renal carcinoma at different stages depending on the imaging modality used

in the czech republic, there is no screening program for renal cell carcinoma. existing evidence suggests that incidental detection of this cancer tends to occur in its early stages, which are more manageable due to effective treatment options, ultimately reducing renal cancer mortality. this highlights the potential value of evaluating current imaging modalities and determining their role in secondary prevention. this cross-sectional study, based on hospital data, aims to contribute to a better understanding of this issue and to assess the effectiveness of imaging techniques in the early detection of renal cell carcinoma. furthermore, data analysis may reveal the influence of risk factors on the detection of tumors at various stages.

Eligibility criteria:
inclusion criteria: * patients over 18 years of age undergoing surgical treatment for renal lesions exclusion criteria: * patients undergoing surgery for non-renal and urotelial carcinoma, including unknown * patients with recurrent renal lesions

Keywords: renal cell carcinoma detection imaging modalities non-neoplastic renal lesions
comparison between deep dry needling and muscle energy technique on chronic non-specific neck pain patients.

Conditions: Neck Pain

Summary: the goal of this clinical trial is to compare between applying deep dry needling and muscle energy technique in chronic non-specific neck pain patients. researchers will compare between deep dry needling group, muscle energy technique group and control group to see if there are change in pain, range of motion or function.


Eligibility criteria:
inclusion criteria: 1. age 18 and 40 years. 2. current neck pain. 3. presence of at least one or two trigger points . 4. patients are diagnosed and referred from orthopedist complaining from chronic neck pain for at least 12 weeks. 5. no clinical treatment for neck pain within the past month. 6. lacked a history of neck and shoulder myopathy, neuropathy, myelopathy and neck, torso and shoulder surgery. 7. patients with body mass index less than 30 kg/m2. exclusion criteria: 1. patients outside the target range. 2. neck pain associated with vertigo. 3. osteoporosis. 4. diagnosed psychological disorders. 5. fibromyalgia syndrome. 6. vertebral fractures. 7. spinal stenosis. 8. tumors. 9. previous neck surgery. 10. red flags (night pain, severe muscle spasm, loss of involuntary weight, symptom mismatch). 11. physiotherapeutic treatment continued in the last 3 months. any contraindications for deep dry needling such as anticoagulants, infections and bleeding.
a pharmacokinetic study of ro4917523 in healthy japanese and caucasian subjects

Conditions: Healthy Volunteer

Summary: this double-blind, randomized, placebo-controlled, 2-part study will evaluate the pharmacokinetics and safety of ro4917523 in healthy japanese and caucasian volunteers. in part 1, healthy japanese volunteers will be randomized to receive 2 oral doses of either ro4917523 or placebo, with a washout period of 21 days between dosing. in part 2, healthy japanese and caucasian volunteers will be randomized in cohorts to receive either ro4917523 or placebo orally daily for 14 days.


Eligibility criteria:
inclusion criteria: * healthy japanese (part 1 + 2) or caucasian (part 2) adults, 18- 50 years of age * japanese subjects must have japanese parents and grandparents who were born in japan * caucasian subjects must have 4 caucasian grandparents * body mass index (bmi) 18.5 to 26 kg/m2, and a body weight of at least 45 kg * non-smoker for at least 90 days prior to dosing day 1 exclusion criteria: * participation in a clinical trial with an investigational drug within 90 days prior to dosing day 1. (volunteers having participated in part 1 will not be allowed to participate in part 2 and vice versa) * history or evidence of any clinically significant disease or disorder * pregnant or lactating women * positive for hepatitis b, hepatitis c or hiv * positive drug screen test, positive cotinine test and/or positive alcohol test * any confirmed significant allergic reactions to any drug, or multiple allergies in the judgement of the investigator
airway manoeuvers - implications for airway management?

Conditions: Airway Management

Summary: in anesthesia, intubation is a technique used to secure an airway. this technique is not always straightforward. sometimes it is difficult to place an endotracheal tube. there are two manners of giving pressure to the patients neck, to improve view and facilitate intubation. the investigators hypothesize that by giving this pressure the effective work area is likely to be smaller. the investigators would like to quantify this effect by measuring the effective work area, using a specially designed computer program.

cricoid pressure (cp) and the backward-upward-rightward pressure (burp) manoeuver, are extralaryngeal manoeuvers which are widely applied during endotracheal intubation, respectively offering potential protection against passive gastric regurgitation and improved laryngeal view in emergency airway management. their validity in achieving an improvement of the laryngeal view has been questioned. the objective of this study is to measure the change in mean anterior-posterior rima glottidis (aprima) distance and mean area under the vocal cords after backward upward rightward pressure (burp) and cricoid pressure (cp). the investigators will measure the aprima distances and areas under the vocal cords, using a specially created module in the program devide. the measurements assessed during burp and cp will be expressed relative to the measurements when no external pressure is applied.

Eligibility criteria:
inclusion criteria: - 200 consecutive adult patients scheduled for elective surgery requiring endotracheal intubation exclusion criteria: * bmi \> 35 kg.m-2); * chronic obstructive pulmonary disease; * history of difficult intubation; * mouth opening \< 3 cm; * inadequate neck mobility; * history of oropharyngeal pathology.

Keywords: cricoid pressure (cp) backward upward rightward pressure (burp) ap-rima distances glottic area extralaryngeal manoeuvres
exogenous ketone supplementation and cognitive function during exercise

Conditions: Ketonemia; Mental Fatigue; Ketosis

Summary: 15 healthy trained males will volunteer to participate in this study. there will be 2 treatments: ketone esters supplementation and iso-caloric carbohydrate. the purpose of this study is to evaluate the effect of ketone esters on cognitive function during exercise after induced mental fatigue

mental fatigue is often seen in sports of moderate to long duration. its onset is associated with detriments in cognitive function which leads to poor decision making and detriments in specific sport skills. ketones can serve as a powerful brain fuel source so they may have the potential to delay/ revert the onset of mental fatigue. in this experiment, we will induce mental fatigue in individuals who will be performing 45 minutes of intermittent exercise right after. during exercise cognitive function will be measured under 2 condition, ketone supplementation and placebo. the purpose of this study is to see if ketones can play a role in reverting that initial mental fatigue during exercise, compared to placebo.

Eligibility criteria:
inclusion criteria: * in order to be eligible to participate in this study you must be a healthy male or female recreationally active individual, 18-35 year old. exclusion criteria: * you will be excluded from this study if you: * are not involved in regular exercise (at least 2x week) * have symptoms or take medication for respiratory, cardiovascular, metabolic, neuromuscular disease * use any medications with side effects of dizziness, lack of motor control, or slowed reaction time * are taking part in another research study * for women, if you are pregnant or become pregnant during the study. * have a history of concussion/head injuries. * have an excessive alcohol intake (\>2 drinks/day) * are consuming a ketogenic diet (for at least 2 weeks) * are a smoker * \*\* cannabis use is not a exclusion criteria; however, it must be avoided on experimental days.\*\*

Keywords: ketone supplements cognitive function exercise
respiratory consequences of n95-type mask usage in pregnant healthcare workers - a controlled clinical study

Conditions: Hypoventilation

Summary: the study aims to find out if usage of n95 type respirators affects respiratory parameters in pregnant women so as to provide guidance on n95 respirator usage in pregnant healthcare workers.

the first phase of the study aims to determine the average workload of a nurse. in the second phase of the study, this workload is then translated to walking on a treadmill while pregnant subjects wore special masks open to air, then occluded with n95 mask materials.

Eligibility criteria:
inclusion criteria: * subjects had spontaneously conceived singleton pregnancies and were between 21 to 40 years old. their hemoglobin levels were ≥11g/dl exclusion criteria: * any cardiorespiratory illness, influenza-like illness in the week prior to the trial, or any pregnancy-related complications such as gestational diabetes, hypertension, intrauterine growth restriction, placenta previa, ruptured membranes, or threatened preterm labor. any neuromuscular conditions that would preclude them from using the treadmill. haemoglobinopathies.

Keywords: filtering facepiece respirators n95 masks pandemic response pregnant healthcare workers
a multiple dose study of pf-04620110 in overweight and obese, otherwise healthy volunteers

Conditions: Obesity; Overweight; Healthy

Summary: pf-04620110 is a novel compound proposed for the treatment of type 2 diabetes mellitus. the primary purpose of this trial is to evaluate the safety and tolerability, pharmacokinetics, and pharmacodynamics, of multiple oral doses of pf-04620110.


Eligibility criteria:
inclusion criteria: * healthy male and/or female subjects between the ages of 18 and 55 years * body mass index (bmi) of 26.5 to 35.5 kg/m2; and a total body weight \>50 kg (110 lbs). exclusion criteria: * evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or allergic (including drug allergies, but excluding untreated, asymptomatic, seasonal allergies at time of dosing) disease or clinical findings at screening.

Keywords: - mutliple ascending dose study in overweight subjects - body weight - signs and symptoms
antioxidant supplement and reduction of metachronous adenomas of the large bowel: a double blind randomized trial

Conditions: Colorectal Adenomas

Summary: the trial was aimed at evaluating the efficacy of a multiagent antioxidant compound (vitamin a, c, e, selenium and zinc) in reducing the incidence of metachronous adenomas of the large bowel after endoscopic polypectomy. this is a randomized study: a 50% reduction in the incidence of metachronous adenomas was expected in patients allocated to the "active" compound (intervention) arm as compared to those assigned to a placebo.

adenomatous polyps (or adenoma) are benign lesions of the large bowel that are frequent in people aged 60 or more: about one in four of them has at least one adenoma. in time, adenoma could progress to cancer. even though only a small rate of adenomas will develop into cancer almost 70-80% of colorectal cancer origin from an adenoma and colorectal cancer is one of the most frequent malignant tumors in the western world. several epidemiological studies showed that subjects who had low intake and/or low blood levels of selenium were at increased risk of developing colorectal cancer.

Eligibility criteria:
inclusion criteria: * age 25-75 years * at least one histologically confirmed adenoma endoscopically removed from the large bowel resulting in a polyp-free colon-rectum (clean colon). exclusion criteria: * polypectomy performed more than 6 months before enrolment in the trial * history of familial adenomatous polyposis * inflammatory bowel disease * adenoma with invasive carcinoma * ten or more adenomas * large sessile adenoma (3 cm or more * colorectal resection * invasive cancer at any site * life-threatening and/or chronic heart, liver or kidney diseases * current use of vitamin or calcium supplements * mental disability

Keywords: chemoprevention colorectal cancer metachronous adenoma randomized trial
ecg validation study

Conditions: Atrial Fibrillation

Summary: subjects will be recruited and begin the study as they are identified and consent to the study. recruiting can end when 140 subjects have initiated the study. the study does allow for additional subjects to be recruited if resources allow, leading to approximately 160 subjects. at the approximate midpoint of the study, intermediate data analysis will be performed. enrollment will continue while this occurs. upon arrival to the clinic on the day of the study visit, prior to the application of the reference and test devices, skin inspection of the application site will be conducted. the reference ecg device will be applied, and two initial ecgs will be taken. the precordial leads from the reference device will then be removed from the patient and the cpm device will be applied to the participant's chest as described in the ifu materials supplied with the device (the study team will also have received training on the proper placement of the device prior to the initiation of the study). this device will be worn for the remainder of the clinic visit. on the crf, the time that the cpm device is placed on the chest will be denoted. the reference device and the test device will then take 2 additional ecg measurements simultaneously. during ecg measurements involving cpm device, it will be helpful to maintain silence during the entire measurement duration, as it helps the device to gather heart sounds signals without interference. the ecg results will be analyzed by certified medical personnel, where they will be asked to annotate various parameters of the ecgs. the certified medical personnel will then be asked to classify the ecgs and about the strips' clinical usability.


Eligibility criteria:
inclusion criteria: * able to provide written, informed consent * individuals 18 years of age and older * willing and able to participate in the study procedures * if in af cohort: subjects must have a known diagnosis of af exclusion criteria: * known allergy or sensitivity to ecg electrodes or any other silicone-based electrodes * injury or skin disturbance in the area of the test device or reference device * acute myocardial infarction within 90 days of screening or other cardiovascular diseases that increases subject risk or renders data uninterpretable (by discretion of the investigator) * stroke or tia within 90 days of screening * significant tremor that prevents subject from being still * history of abnormal life-threatening arrhythmias (by discretion of the investigator) * pregnant (method of assessment at study physician's discretion)
nasal provocation test with lysine-acetylsalicylate (asa) in patients with nonsteroidal anti-inflammatory drugs (nsaids) hypersensitivity

Conditions: Aspirin Hypersensitivity; NSAIDs Hypersensitivity

Summary: this study aims to compare the efficacy of nasal provocation test with lysine-acetylsalicylate in patients with history of nsaids hypersensitivity between mucocutaneous symptoms and respiratory symptoms and laboratory outcomes.


Eligibility criteria:
inclusion criteria: * patients with history of asa/nsaids hypersensitivity with mucocutaneous symptoms and/or respiratory symptoms exclusion criteria: * patients who cannot discontinue drugs before the test as follow * nasal corticosteroids/oral corticosteroids/leukotriene modifiers for 1 week * short-acting antihistamines for 3 days * nasal a-mimetics/oral a-mimetics/local cromones for 24 hours * contraindicated for nasal provocation test: pregnant, exacerbation of allergic rhinitis/asthma, having upper respiratory tract infection within 2 weeks prior to the test, having nose surgery within 8 weeks prior to the test, having severe systemic disease(s) * having factors interfere nasal provocation test with lysine-asa such as massive nasal polyp, nasal septal perforation, total nasal obstruction at least 1 nostril
an observational, retrospective multicentre medical record review to describe the post-authorisation early clinical experience of dupilumab in the treatment of adult severe asthma

Conditions: Asthma

Summary: the purpose of this retrospective medical record review is to describe the real-world clinical effectiveness of dupilumab with patients in the united kingdom with severe asthma.

participants initiating treatment with dupilumab in the uk between 5th july 2019 and 12th august 2021 will be included in the study record review, permitting participation in research and if medical records are available for review. no intervention will be administered in this clinical trial. data will be collected from hospital medical records and other hospital databases.

Eligibility criteria:
inclusion criteria: • adult participants (aged ≥18 years at index) with severe asthma, initiated with dupilumab treatment (≥1 dose) between 07/05/2019 (eu licence) and 08/12/2021 • participants with ≥1 routine asthma clinic visit recorded within 6 months prior to or on the date of dupilumab initiation and ≥1 routine asthma clinic visit recorded between 9 and 16 months post-dupilumab initiation exclusion criteria: • participants known to have opted out of participation in research • participants whose medical records are not available for review the above information is not intended to contain all considerations relevant to a potential participation in a clinical trial.
study of combined topical growth factor and protease inhibitor in chronic wound healing

Conditions: Venous Ulcer; Foot Ulcer, Diabetic

Summary: leg and foot ulcers due to venous disease or diabetes are chronic wounds that can take 6 or more months to heal. growth factors have been used to try and improve this healing, however, many such studies have failed, and that is thought to be due enzymes in the wound that degrade the growth factors and prevent them from working. this is a proof of concept study that will evaluate the treatment of chronic leg ulcers with topically applied growth factors that are combined with a therapy to prevent their inactivation in the wound.


Eligibility criteria:
inclusion criteria: * men and women aged ≥18 years * ulcer size 1-64 cm² * ulcer extends through both the epidermis and dermis, with no exposed tendon or bone * ulcer duration \>3 months * ulcer located between and including the knee and ankle * for venous leg ulcers - venous refilling time \<25s on photoplethysmography or abnormal venous insufficiency duplex scan * for diabetic foot ulcers - confirmed type 1 or type 2 diabetes mellitus with a haemoglobin a1c \< 12% * wounds have not been treated with promogran in the previous 4 weeks * patients able to give informed consent exclusion criteria: * ankle-brachial index \<0.8 * ulcer with local or systemic signs of infection * patients who have been previously treated with becaplermin gel * receiving corticosteroids or immune suppressants * history of autoimmune disease * uncontrolled diabetes (baseline haemoglobin a1c \> 12%) * severe rheumatoid arthritis * uncontrolled congestive heart failure * malnutrition (albumin \<2.5g/dl) * unable to adhere to the protocol * known sensitivities to the wound dressings used in the trial * a history of any previous malignancy * pregnant or lactating women

Keywords: venous leg ulcer diabetic foot ulcer wound healing growth factor protease inhibitor
nucleoside (acid) analogues treatment in patients with normal alt and positive hbvdna.

Conditions: Hepatitis B Virus

Summary: this study is to investigate the clinical efficacy and safety of nucleoside (acid) analogues treatment in patients with normal alanine aminotransferase and positive hepatitis b virus dna.

hepatitis b virus infection has always been a global public health problem that endangers national health. current clinical guidelines do not recommend antiviral therapy for people with positive hepatitis b-dna and normal alanine aminotransferase, but studies have found that viral replication is associated with an increased risk of cirrhosis and liver tumors. nucleoside (acid) analogues can effectively inhibit viral reverse transcriptase, reduce hbv viral load in the blood, thereby reducing secondary inflammation, and contribute to liver cell regeneration and disease recovery. and its side effect is small, adverse reaction rate is low, use safety.

Eligibility criteria:
inclusion criteria: * positive hepatitis b surface antigen and hepatitis b antibody \> 0.5 year; * age from 18 to 65 years old; * serum alanine aminotransferase(alt) ≤1×uln at least 12 weeks; * positive hepatitis b virus(hbv); * do not receive nucleotide/nucleoside analogues or interferon treatment in the past half year. exclusion criteria: * other active liver diseases; * hepatocellular carcinoma or other malignancy; * pregnancy or lactation; * human immunodeficiency virus infection or congenital immune deficiency diseases; 5.severe diabetes, autoimmune diseases; 6.other important organ dysfunctions; 7.using glucocorticoid; 8.patients can not follow-up; 9.investigator considering inappropriate.

Keywords: hepatitis b virus nucleoside nucleotide